Back to results
US 12,005,111 B2Granted
Zika virus vaccine
AssigneeValneva Austria GmbH
InventorsJana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
Life of this patent
Estimating the term…
Abstract
Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Claims58
A Zika virus vaccine comprising a Zika virus having an RNA genome corresponding to the DNA sequence provided by SEQ ID NO:
- 13 or a variant nucleic acid having at least 99% identity to SEQ ID NO:
- 13, wherein the sequence identity is determined by Needleman-Wunsch homology alignment, wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects,
- wherein the neutralizing antibody titer is determined using a microneutralization assay (MN50) following a single administration of the Zika virus vaccine to a subject;
- and
- wherein the Zika virus comprises an E protein having an amino acid sequence provided by SEQ ID NO:
- 48 and is able to pack a virulent Zika virus.
3 more elements
A Zika virus vaccine comprising a Zika virus having an RNA genome corresponding to a DNA sequence having at least 99.9% identity to SEQ ID NO:
- 13, wherein the sequence identity is determined by Needleman-Wunsch homology alignment, wherein said Zika virus vaccine is capable of stimulating a neutralizing antibody titer greater than 15 in at least 70% of vaccinated subjects, wherein the neutralizing antibody titer is determined using a microneutralization assay (MN50) following a single administration of the Zika virus vaccine to a subject;
- wherein the Zika virus comprises an E protein having an amino acid sequence provided by SEQ ID NO:
- 48;
- and
- wherein the Zika virus is Vero cell adapted and is able to pack a virulent Zika virus.
2 more elements
Dependencies are inferred from the claim text.